Gram-positive bacterial cell wall components inhibit herpes simplex virus infection

Journal Article · Wed Apr 01 00:00:00 EDT 2026 · bioRxiv

DOI:https://doi.org/10.1101/2025.11.02.686169· OSTI ID:3028830

Adams,; Griffin,; Burnie,; Powers,; Causey,; Glick,; Gavitt,; Richmond-Buccola,; Kim,; Ahmad,; Jackson,; Keiser,; Cheng,; Kumar,; Fernando,; Vlach,; Orzalli,; Corbett-Helaire,; Decout,; Azadi, ; Gopinath,

The role of the mucosal microbiome in viral infections remains unclear. Genital herpes, caused by herpes simplex virus 1 and 2 (HSV-1 and HSV-2), is among the most prevalent sexually transmitted infections worldwide. Despite evidence linking vaginal Lactobacillus to protection against sexually transmitted viruses, the specific microbial components and mechanisms that mediate this defense are not well understood. Here, we show that multiple cell wall components from diverse gram-positive bacteria, including lactobacilli, inhibit HSV-1 and HSV-2 infection in cells and in a mouse model of genital herpes infection. Peptidoglycan (PG) and lipoteichoic acid (LTA), both major components of the gram-positive bacterial cell wall, significantly reduced HSV infectivity in vitro and improved survival and disease outcomes in mice. We further showed that Lactobacillus crispatus surface layer proteins SlpA and SlpB bind HSV-1 and inhibit infection. Antiviral effects of cell wall components were dose-dependent, relied on intact PG structure, and, in the case of PG and LTA, were independent of TLR2-mediated host signaling. Collectively, our findings identify a species-independent antiviral function for gram-positive bacterial cell wall components against HSV and suggest that the composition of the mucosal microbiome may play an underappreciated role in suppressing mucosal herpes infection in humans.

• Research Organization: University of Georgia Research Foundation, Inc.
• Sponsoring Organization: USDOE Office of Science (SC), Basic Energy Sciences (BES). Chemical Sciences, Geosciences & Biosciences Division (CSGB)
• Grant/Contract Number: SC0015662
• OSTI ID: 3028830
• Journal Information: bioRxiv, Journal Name: bioRxiv
• Country of Publication: United States
• Language: English